Cancer Nanovaccines In article number 2104849, Mi Liu and co-workers demonstrate a simple universal method to prepare therapeutic preventive cancer nanovaccines based on tumor tissues/cells. Such show both potent efficacy in lung cancer, melanoma, breast cancer. This can be applied make tumor-cell-based for immunotherapy prevention.

Recent deals involving bispecific antibodies illustrate the growing breadth of cancer immunotherapy applications for this platform.

Breast cancer is the most commonly diagnosed cancer among women. Therapeutic treatments for breast cancer generally include surgery, chemotherapy, radiotherapy, endocrinotherapy and molecular targeted therapy. With the development of molecular biology, immunology and pharmacogenomics, immunotherapy becomes a promising new field in breast cancer therapies. In this review, we discussed recent pro...

Immunotherapy has been one of the standard treatment options for lung cancer. Biomarkers such as PD-L1 and TMB have a certain predictive role on efficacy. At same time, studies also found that EGFR mutations ALK fusions were inversely related to efficacy immunotherapy. The MYSTIC trial evaluated STK11, KEAP1, ARID1A, KRAS their correlation with immune results showed STK11 and/or KEAP1 had poor ...

In recent years, cancer immunotherapy research has made remarkable progress, completely transforming the treatment landscape [...]

Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These in...

With the development of cancer immunotherapy, cancer vaccine has become a novel modality for cancer treatment, and the important role of adjuvant has been realized recently. Chitin, chitosan, and their derivatives have shown their advantages as adjuvants for cancer vaccine. In this paper, the adjuvant properties of chitin and chitosan were discussed, and some detailed information about glycated...

Background Since its inception, the Journal for Immunotherapy of Cancer (JITC) has focused on all aspects of tumor immunology and cancer immunotherapy from bench to bedside. Clinical advances in immuno-oncology are accelerating, with an increasing number of approved drugs that specifically target the immune system to treat cancer. The success of these agents in the clinic has given rise to a ra...

The past several years have witnessed a revival of interest in cancer immunology and immunotherapy owing to striking immunologic and clinical responses to immune-directed anticancer therapies and leading to the selection of "Cancer Immunotherapy" as the 2013 Breakthrough of the Year by Science. But statistical challenges exist at all phases of clinical development. In phase III trials of immuno...